Nagpur, Maharashtra
GST No. 27AYDPV1020G2ZN
Approx. Rs 21,000 / BoxGet Latest Price
Product Details:| Minimum Order Quantity | 1 Box |
| Brand | ototropin |
| Total Strength | 100 IU |
| Form | Vial |
| Packaging Size | 5 Vials/Kit |
| Hormone Type | Somatropin |
| Usage / Application | Bodybuilding |
| Country of Origin | India |
| Kit Contents | Bacteriostatic WTR |
| made by | denik pharma |
| unit size | 20 iu vial |
| Contents | hGH (191aa Human Growth Hormone) lyophilised powder 20iu x 5 vials Ampoule: 2ml Sterile water for injection. |
| Administration | Intramuscular or Subcutaneous injection. |
| Storage | Store at room temperature away from heat and direct sunlight pre reconstitution. Refrigerate between 2-8’C post Reconstitution. |
| Dosage | Adult: SC Growth hormone deficiency Initial: 6 mcg/kg/day. May increase dose gradually. Max: 12.5 mcg/kg/day. HIV-associated wasting or cachexia 0.1 mg/kg/day at bedtime. May take on alternate days for patients at increased risk of adverse effects. Max: 6 mg/day. Short bowel syndrome100 mcg/kg/day for 4 wk. Max: 8 mg/day. |
| Contraindications | Acute critical illness due to heart or abdominal surgery, multiple accidental trauma or respiratory failure; active neoplasms, proliferative or preproliferative diabetic retinopathy; lactation; patients with closed epiphyses. Intracranial lesions. Patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment. |
| Special Precautions | Monitor thyroid function; benign intracranial hypertension. DM; may require dose reduction in insulin. Pregnancy. Discontinue treatment if there is evidence of tumour growth. Monitoring in patients with scoliosis is recommended due to risk of progression of scoliosis. |
| Adverse Drug Reactions | Hypothyroidism, peripheral oedema; headache; muscle and joint pain; benign intracranial hypertension. Loss of glycaemic control in diabetics. |
| Drug Interactions | High doses of corticosteroid may inhibit growth-promoting effects of somatropin. |
| Pregnancy Category (US FDA) | Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1sttrimester (and there is no evidence of a risk in later trimesters). |
| ATC Classification | H01AC01 – somatropin ; |
| Disclaimer | "Images displayed on the website are for representational purposes only which may differ from the actual purchased product. The company may change or alter the packaging design without notice. |
Additional Information:
Approx. Rs 13,000 / BoxGet Latest Price
Product Details:| Minimum Order Quantity | 1 Box |
| Type of Steroid Hormone | Androgens |
| Usage/Application | Personal |
| Form | Injection |
| Packaging Size | 5 VIALS OF 6 MG |
| Purity | 99% |
| Delivery | 10 DAYS |
| Storage Temperature | Store at room temperature away from heat and direct sunlight pre reconstitution.; Refrigerate betwee |
| Country of Origin | Made in India |
| MANUFACTURER | DENIK PHARMA |
| Contents | Vial: GROSIX-DS(GHRP 6) 6mg. Ampoule: 2ml Sterile water for injection. |
| Administration | Intramuscular or Subcutaneous injection. |
| Storage | Store at room temperature away from heat and direct sunlight pre reconstitution.; Refrigerate between;2-8’C post Reconstitution. |
| Dosage | Adult: SC Growth hormone deficiency Initial: 6 mcg/kg/day. May increase dose gradually. Max: 12.5 mcg/kg/day. HIV-associated wasting or cachexia 5 mcg/kg/day at bedtime. May take on alternate days for patients at increased risk of adverse effects. Max: 5 mg/day. |
| Contraindications | Acute critical illness due to heart or abdominal surgery, multiple accidental trauma or respiratory failure; active neoplasms, proliferative or preproliferative diabetic retinopathy; lactation; patients with closed epiphyses. Intracranial lesions. Patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment. |
| Special Precautions | Monitor thyroid function; benign intracranial hypertension. DM; may require dose reduction in insulin. Pregnancy. Discontinue treatment if there is evidence of tumour growth. Monitoring in patients with scoliosis is recommended due to risk of progression of scoliosis. |
| Drug Interactions | High doses of corticosteroid may inhibit growth-promoting effects of GHRP-6. |
| Disclaimer | "Images displayed on the website are for representational purposes only which may differ from the actual purchased product. The company may change or alter the packaging design without notice." |
Additional Information:
Approx. Rs 15,000 / BoxGet Latest Price
Product Details:| Minimum Order Quantity | 1 Box |
| Strength | 125MCG |
| Usage/Application | Personal |
| Packaging Size | 5X1 Vials |
| Brand | INSUGRO |
| Product Type | Finished Product |
| Delivery | 10 DAYS |
| Storage Temperature | Store at room temperature away from heat and direct sunlight pre reconstitution. Refrigerate between |
| Purity | 99% |
| Country of Origin | Made in India |
| MANUFACTURER | DENIK PHARMA |
| Contents | Vial: IGF1(Insulin-Like Growth Factor1) Long R3 125mcg. Ampule: 2ml Sterile water for injection. |
| Administration | Intramuscular injection. |
| Storage | Store at room temperature away from heat and direct sunlight pre reconstitution. Refrigerate between 2-8’C post Reconstitution. |
| Dosage | Initial: .5 mcg/kg/day. May increase dose gradually. Max: 5 mcg/kg/day. Maximum period for administration 45 days. |
| Contraindications | Acute critical illness due to heart or abdominal surgery, multiple accidental trauma or respiratory failure; active neoplasms, proliferative or pre-proliferative diabetic retinopathy; lactation; patients with closed epiphyses. Intracranial lesions. Patients with Prader-Willi syndrome who are severely obese or have a severe respiratory impairment. |
| Special Precautions | Monitor thyroid function; benign intracranial hypertension. DM; may require dose reduction in insulin. Pregnancy. Discontinue treatment if there is evidence of tumor growth. Monitoring in patients with scoliosis is recommended due to a risk of progression of scoliosis. |
| Adverse Drug Reactions | Side effects noted are tiredness, feeling of lethargy, head rush or euphoria, itching. |
| Drug Interactions | High doses of corticosteroid may inhibit growth-promoting effects of IGF1LR3. |
| Disclaimer | "Images displayed on the website are for representational purposes only which may differ from the actual purchased product. The company may change or alter the packaging design without notice." |
Additional Information:
Approx. Rs 14,000 / BoxGet Latest Price
Product Details:| Minimum Order Quantity | 1 Box |
| Form | Injection |
| Packaging Type | Box |
| Packaging Size | 5 VIALS OF 6 MG |
| Purity | 99% |
| Brand | DENIK PHARMA |
| Country of Origin | Made in India |
| BRAND NAME | GROWTWO |
| SHELF LIFE | 24 MONTHS |
| Contents | Vial: GHRP-2 (Growth Hormone Releasing peptide-2) 6mg. Ampoule: Sterile water for injection 2ml. |
| Administration | Intramuscular or subcutaneous injection. |
| Storage | Store at room temperature away from heat and direct sunlight prior to reconstitution. Refrigerate between 2-8’C post reconstitution. |
| Dosage | Adult: SC Growth hormone deficiency Initial: 6 mcg/kg/day. May increase dose gradually. Max: 12.5 mcg/kg/day. HIV-associated wasting or cachexia 5 mcg/kg/day at bedtime. May take on alternate days for patients at increased risk of adverse effects. Max: 5 mg/day. |
| Contraindications | Acute critical illness due to heart or abdominal surgery, multiple accidental trauma or respiratory failure; active neoplasms, proliferative or preproliferative diabetic retinopathy; lactation; patients with closed epiphyses. Intracranial lesions. Patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment. |
| Special Precautions | Monitor thyroid function; benign intracranial hypertension. DM; may require dose reduction in insulin. Pregnancy. Discontinue treatment if there is evidence of tumour growth. Monitoring in patients with scoliosis is recommended due to risk of progression of scoliosis. |
| Adverse Drug Reactions | Hypothyroidism, peripheral oedema; headache; muscle and joint pain; benign intracranial hypertension. Loss of glycaemic control in diabetics. |
| Drug Interactions | High doses of corticosteroid may inhibit growth-promoting effects of GHRP-2. |
| Disclaimer | "Images displayed on the website are for representational purposes only which may differ from the actual purchased product. The company may change or alter the packaging design without notice." |
Additional Information:
Approx. Rs 15,000 / BoxGet Latest Price
Product Details:| Minimum Order Quantity | 1 Box |
| Type of Steroid Hormone | Glucocorticoids |
| Usage/Application | Personal |
| Form | Injection |
| Packaging Size | 5 vials per box |
| Purity | 99% |
| Delivery | 12 to 15 days |
| Country of Origin | Made in India |
Additional Information:
Approx. Rs 16,000 / BoxGet Latest Price
Product Details:| Minimum Order Quantity | 1 Box |
| Form | Injection |
| Packaging Type | Box |
| Packaging Size | 5 vials per box |
| Purity | 99% |
| Usage/Application | i.m |
| Brand | denik pharma |
| Country of Origin | Made in India |
| Contents | Vial: CJC-1295 with DAC 2mg. Ampoule: 2ml Sterile water for injection. |
| Administration | Intramuscular or Subcutaneous injection. |
| Storage | Store at room temperature away from heat and direct sunlight pre reconstitution. Refrigerate between 2-8’C post Reconstitution. |
| Dosage | Adult: SC Growth hormone deficiency Initial: 2 mcg/kg/day. May increase dose gradually. Max: 10 mcg/kg/day. |
| Contraindications | Acute critical illness due to heart or abdominal surgery, multiple accidental trauma or respiratory failure; active neoplasms, proliferative or preproliferative diabetic retinopathy; lactation; patients with closed epiphyses. Intracranial lesions. Patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment. |
| Special Precautions | Monitor thyroid function; benign intracranial hypertension. DM; may require dose reduction in insulin. Pregnancy. Discontinue treatment if there is evidence of tumour growth. Monitoring in patients with scoliosis is recommended due to risk of progression of scoliosis. |
| Adverse Drug Reactions | Water retention, tingling, numbness and decreased insulin can be associated with use of CJC 1295. Also noted is tiredness, feeling of lethargy, head rush or euphoria, itching. Loss of glycaemic control in diabetics. |
| Drug Interactions | High doses of corticosteroid may inhibit growth-promoting effects of HGH |
| Pregnancy Category (US FDA) | Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1sttrimester (and there is no evidence of a risk in later trimesters). |
Additional Information:
Approx. Rs 21,000 / BoxGet Latest Price
Product Details:| Minimum Order Quantity | 1 Box |
| Form | Injection |
| Packaging Type | Box |
| Packaging Size | 5 VIALS OF 5MG |
| Purity | 99 % |
| Brand | DENIK PHARMA |
| Country of Origin | Made in India |
| BRAND NAME | FRAG RIP |
| Contents | Vial: Tyr-hGH Fragment 177-191 lyophilised powder 5mg x 5 vials Ampoule: 2ml Sterile water for injection. |
| Administration | Intramuscular or Subcutaneous injection. |
| Storage | Store at room temperature away from heat and direct sunlight pre reconstitution. Refrigerate between 2-8’C post Reconstitution. |
| Dosage | Initial: 5 mcg/kg/day empty stomach. May increase dose gradually. Max: 12 mcg/kg/day. |
| Contraindications | Acute critical illness due to heart or abdominal surgery, multiple accidental trauma or respiratory failure; active neoplasms, proliferative or pre-proliferative diabetic retinopathy; lactation; patients with closed epiphyses. Intracranial lesions. Patients with Prader-Willi syndrome who are severely obese or have a severe respiratory impairment. |
| Special Precautions | DM; may require dose reduction in insulin. Pregnancy. Discontinue treatment if there is evidence of tumor growth. Monitoring in patients with scoliosis is recommended due to a risk of progression of scoliosis. |
| Adverse Drug Reactions | Side effects noted are tiredness, feeling of lethargy, head rush or euphoria, itching. Loss of glycaemic control in diabetics. |
| Drug Interactions | High doses of corticosteroid may inhibit growth-promoting effects of HGH Fragment 177-191 |
| Disclaimer | "Images displayed on the website are for representational purposes only which may differ from the actual purchased product. The company may change or alter the packaging design without notice." |
Additional Information:
Explore More Products
© A M Traders. All Rights Reserved (Terms of Use)
Developed and Managed by IndiaMART InterMESH Limited